Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 04/17/2026 | PUT | $25.00 | 3,734 | +2,307 | +161.67% |
| 06/18/2026 | CALL | $50.00 | 18,977 | +1,985 | +11.68% |
| 05/15/2026 | PUT | $20.00 | 1,502 | +1,500 | +75,000.00% |
| 04/17/2026 | CALL | $36.00 | 10,828 | +1,448 | +15.44% |
| 06/18/2026 | PUT | $35.00 | 21,576 | +874 | +4.22% |
| 05/15/2026 | CALL | $40.00 | 21,536 | +754 | +3.63% |
| 06/18/2026 | PUT | $40.00 | 21,257 | -135 | -0.63% |
| 12/18/2026 | CALL | $50.00 | 10,766 | -144 | -1.32% |
| 07/17/2026 | CALL | $55.00 | 1,417 | -159 | -10.09% |
| 04/24/2026 | CALL | $37.00 | 356 | -174 | -32.83% |
| 09/18/2026 | CALL | $80.00 | 7,472 | -175 | -2.29% |
| 04/17/2026 | PUT | $45.00 | 14,803 | -1,255 | -7.82% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Harbor Capital Appreciation Fund | 0.18% | 3.11M | 481.53M |
| Washington Mutual Investors Fund | 0.09% | 1.51M | 234.45M |
| Vanguard U.S. Growth Fund | 0.07% | 1.27M | 196.47M |
| Loomis Sayles Growth Fund | 0.07% | 1.18M | 183.13M |
| Fidelity Blue Chip Growth Fund | 0.07% | 1.13M | 175.35M |
| Amana Mutual Funds Trust-Growth Fund | 0.06% | 1M | 155.09M |
| PGIM Jennison Growth Fd | 0.05% | 828.11k | 128.15M |
| Blackrock Equity Dividend Fund | 0.04% | 712k | 110.18M |
| New Perspective Fund Inc | 0.04% | 691.44k | 107M |
| Price (T.Rowe) International Stock Fund | 0.04% | 674k | 104.3M |
Nuclear, Pharma and Travel Buybacks: Confident or Cautious Signals?
04/06 11:25 am
Investing.com
Read moreEli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight
04/04 01:32 pm
The Motley Fool
Read moreWhy Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market
04/03 05:02 pm
The Motley Fool
Read moreTrump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: Report
04/02 04:44 am
Benzinga
Read moreWhy Eli Lilly Stock Trounced the Market Today
04/01 06:23 pm
The Motley Fool
Read moreSlash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
03/31 02:35 pm
Benzinga
Read moreHeart Risks Go Beyond the Heart: Don’t Forget to Check Blood Sugar and Kidney Health
03/30 01:33 pm
GlobeNewswire Inc.
Read morePrediction: Buying Pfizer Stock Today Could Set You Up for Life
03/29 08:15 pm
The Motley Fool
Read more1 Reason This Biotech Stock Could Triple Before Year-End
03/29 12:30 am
The Motley Fool
Read moreNovo Nordisk Wins FDA Nod For First-Ever Weekly Basal Insulin
03/27 08:04 am
Benzinga
Read moreNovo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
03/26 07:36 pm
GlobeNewswire Inc.
Read moreCould Buying Eli Lilly Today Set You Up for Life?
03/26 03:15 pm
The Motley Fool
Read moreIs Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?
03/25 09:36 am
Benzinga
Read moreStock Market Today: Dow, Nasdaq Futures Jump Even As Iran Dismisses Trump Talks—Robinhood, Circle, Arm Holdings In Focus (UPDATED)
03/25 08:40 am
Benzinga
Read moreiDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors
03/24 06:00 am
GlobeNewswire Inc.
Read moreIndia's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply
03/23 09:00 am
Benzinga
Read moreShould You Buy Eli Lilly Stock Before April 10?
03/22 05:10 am
The Motley Fool
Read moreNovo Nordisk Secures FDA Approval For Higher-Dose Wegovy
03/19 01:50 pm
Benzinga
Read moreIs It Too Late to Buy Eli Lilly?
03/19 11:15 am
The Motley Fool
Read moreThe Best Healthcare Stocks to Buy With $50 Right Now
03/18 08:30 am
The Motley Fool
Read moreBetter Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics
03/17 08:30 pm
The Motley Fool
Read moreEli Lilly Analyst Flags Overhyped Obesity Drug Expectations
03/17 12:57 pm
Benzinga
Read moreNovo Nordisk A/S Investigated by the Portnoy Law Firm
03/17 09:00 am
GlobeNewswire Inc.
Read moreShould You Avoid Pfizer? Here's the Key Risk to Watch
03/17 01:15 am
The Motley Fool
Read moreAmgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
03/16 07:19 am
Benzinga
Read moreBIO-Europe Spring® 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon
03/16 06:00 am
GlobeNewswire Inc.
Read moreIs Eli Lilly's Weight Loss Empire in Trouble?
03/13 06:30 pm
The Motley Fool
Read moreThe Real Reason Eli Lilly Is Pouring $3 Billion Into China
03/13 01:21 pm
Investing.com
Read moreNovo Holdings announces 2025 Annual Results
03/12 03:00 am
GlobeNewswire Inc.
Read moreForget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner
03/11 02:30 pm
The Motley Fool
Read more2 Healthcare Stocks That Are Too Cheap to Ignore
03/10 12:23 pm
The Motley Fool
Read moreEurope In Review: Natural Gas Prices Spike As Europe Splits Over US‑Israeli Strikes
03/10 10:47 am
Benzinga
Read moreStock Market Today: Dow, Nasdaq 100, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike— Hims & Hers In Focus (UPDATED)
03/09 09:17 am
Benzinga
Read moreRoche's Breast Cancer Drug Falls Short In Phase 3 Study
03/09 08:09 am
Benzinga
Read moreHims & Hers, Novo Nordisk Weight-Loss Drug Deal Ends Legal Feud, Stock Soars
03/09 07:04 am
Benzinga
Read moreBetter Weight Loss Stock: Novo Nordisk Vs. Amgen
03/08 02:30 pm
The Motley Fool
Read moreWhere Will Eli Lilly Stock Be in 10 Years?
03/07 12:15 pm
The Motley Fool
Read moreDown but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
03/06 07:05 pm
The Motley Fool
Read moreChina Clears Weight-Loss Shot As Pfizer Enters Crowded Market
03/06 09:14 am
Benzinga
Read moreRoche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly
03/06 07:47 am
Benzinga
Read moreNovo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors
03/05 05:05 pm
The Motley Fool
Read moreGLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026
03/05 11:58 am
GlobeNewswire Inc.
Read moreLooking For A Rebound? China Tech and Emerging Markets Top Oversold List
03/04 01:41 pm
Benzinga
Read moreGLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - Clinical Trials Exploring GLP-1 Role in NAFLD and NASH Unlock Future Opportunities
03/04 06:48 am
GlobeNewswire Inc.
Read moreShould You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
03/03 04:14 pm
The Motley Fool
Read moreElection of employee representatives to the Board of Directors of Novo Nordisk A/S
03/02 11:55 am
GlobeNewswire Inc.
Read moreNovo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland
03/02 05:00 am
GlobeNewswire Inc.
Read more